Financial - Conglomerates
Compare Stocks
4 / 10Stock Comparison
PACS vs CCRN vs HCA vs THC
Revenue, margins, valuation, and 5-year total return — side by side.
Medical - Care Facilities
Medical - Care Facilities
Medical - Care Facilities
PACS vs CCRN vs HCA vs THC — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot | ||||
|---|---|---|---|---|
| Industry | Financial - Conglomerates | Medical - Care Facilities | Medical - Care Facilities | Medical - Care Facilities |
| Market Cap | $5.27B | $423M | $95.95B | $17.01B |
| Revenue (TTM) | $5.29B | $761M | $75.60B | $21.45B |
| Net Income (TTM) | $192M | $-99M | $6.78B | $1.70B |
| Gross Margin | 21.9% | 18.2% | 41.5% | 42.8% |
| Operating Margin | 5.9% | -0.9% | 15.8% | 16.1% |
| Forward P/E | 16.2x | 133.8x | 14.2x | 10.9x |
| Total Debt | $3.20B | $2M | $50.20B | $13.17B |
| Cash & Equiv. | $197M | $109M | $1.04B | $2.88B |
PACS vs CCRN vs HCA vs THC — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
| Stock | Apr 24 | May 26 | Return |
|---|---|---|---|
| PACS Group, Inc. (PACS) | 100 | 134.6 | +34.6% |
| Cross Country Healt… (CCRN) | 100 | 74.4 | -25.6% |
| HCA Healthcare, Inc. (HCA) | 100 | 138.5 | +38.5% |
| Tenet Healthcare Co… (THC) | 100 | 172.9 | +72.9% |
Price return only. Dividends and distributions are not included.
Quick Verdict: PACS vs CCRN vs HCA vs THC
Each card shows where this stock fits in a portfolio — not just who wins on paper.
PACS is the #2 pick in this set and the best alternative if growth exposure is your priority.
- Rev growth 29.3%, EPS growth 221.1%
- 29.3% NII/revenue growth vs CCRN's -21.6%
- +219.6% vs CCRN's -5.4%
CCRN is the clearest fit if your priority is sleep-well-at-night.
- Lower volatility, beta 0.78, Low D/E 0.7%, current ratio 3.78x
HCA carries the broadest edge in this set and is the clearest fit for income & stability and defensive.
- Dividend streak 5 yrs, beta 0.29, yield 0.7%
- Beta 0.29, yield 0.7%, current ratio 0.83x
- 9.0% margin vs CCRN's -13.0%
- Beta 0.29 vs CCRN's 0.78
THC is the clearest fit if your priority is long-term compounding and valuation efficiency.
- 5.2% 10Y total return vs HCA's 450.5%
- PEG 0.33 vs HCA's 0.67
- Lower P/E (10.9x vs 14.2x), PEG 0.33 vs 0.67
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth | 29.3% NII/revenue growth vs CCRN's -21.6% | |
| Value | Lower P/E (10.9x vs 14.2x), PEG 0.33 vs 0.67 | |
| Quality / Margins | 9.0% margin vs CCRN's -13.0% | |
| Stability / Safety | Beta 0.29 vs CCRN's 0.78 | |
| Dividends | 0.7% yield; 5-year raise streak; the other 3 pay no meaningful dividend | |
| Momentum (1Y) | +219.6% vs CCRN's -5.4% | |
| Efficiency (ROA) | 11.3% ROA vs CCRN's -19.8%, ROIC 19.9% vs -0.9% |
PACS vs CCRN vs HCA vs THC — Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
PACS vs CCRN vs HCA vs THC — Financial Metrics
Side-by-side numbers across 4 stocks — who leads on profitability, valuation, growth, and risk.
Who Leads Where
THC leads in 3 of 6 categories
HCA leads 2 • PACS leads 0 • CCRN leads 0 • 1 tied
Explore the data ↓Income & Cash Flow (Last 12 Months)
THC leads this category, winning 4 of 6 comparable metrics.
Income & Cash Flow (Last 12 Months)
HCA is the larger business by revenue, generating $75.6B annually — 99.4x CCRN's $761M. HCA is the more profitable business, keeping 9.0% of every revenue dollar as net income compared to CCRN's -13.0%. On growth, HCA holds the edge at +6.7% YoY revenue growth, suggesting stronger near-term business momentum.
| Metric | ||||
|---|---|---|---|---|
| RevenueTrailing 12 months | $5.3B | $761M | $75.6B | $21.5B |
| EBITDAEarnings before interest/tax | $365M | $9M | $15.5B | $4.3B |
| Net IncomeAfter-tax profit | $192M | -$99M | $6.8B | $1.7B |
| Free Cash FlowCash after capex | $254M | $41M | $7.7B | $3.3B |
| Gross MarginGross profit ÷ Revenue | +21.9% | +18.2% | +41.5% | +42.8% |
| Operating MarginEBIT ÷ Revenue | +5.9% | -0.9% | +15.8% | +16.1% |
| Net MarginNet income ÷ Revenue | +3.6% | -13.0% | +9.0% | +7.9% |
| FCF MarginFCF ÷ Revenue | — | +5.4% | +10.2% | +15.6% |
| Rev. Growth (YoY)Latest quarter vs prior year | — | -100.0% | +6.7% | +2.8% |
| EPS Growth (YoY)Latest quarter vs prior year | +75.0% | -6.0% | +44.6% | +87.6% |
Valuation Metrics
THC leads this category, winning 4 of 7 comparable metrics.
Valuation Metrics
At 12.5x trailing earnings, THC trades at a 55% valuation discount to PACS's 27.6x P/E. Adjusting for growth (PEG ratio), THC offers better value at 0.38x vs HCA's 0.72x — a lower PEG means you pay less per unit of expected earnings growth.
| Metric | ||||
|---|---|---|---|---|
| Market CapShares × price | $5.3B | $423M | $95.9B | $17.0B |
| Enterprise ValueMkt cap + debt − cash | $8.3B | $317M | $145.1B | $27.3B |
| Trailing P/EPrice ÷ TTM EPS | 27.56x | -4.47x | 15.12x | 12.53x |
| Forward P/EPrice ÷ next-FY EPS est. | 16.24x | 133.84x | 14.19x | 10.94x |
| PEG RatioP/E ÷ EPS growth rate | — | — | 0.72x | 0.38x |
| EV / EBITDAEnterprise value multiple | 22.63x | 23.75x | 9.37x | 6.34x |
| Price / SalesMarket cap ÷ Revenue | 1.00x | 0.40x | 1.27x | 0.80x |
| Price / BookPrice ÷ Book value/share | 5.53x | 1.31x | — | 1.97x |
| Price / FCFMarket cap ÷ FCF | — | 10.55x | 12.47x | 6.72x |
Profitability & Efficiency
HCA leads this category, winning 5 of 9 comparable metrics.
Profitability & Efficiency
PACS delivers a 20.1% return on equity — every $100 of shareholder capital generates $20 in annual profit, vs $-27 for CCRN. CCRN carries lower financial leverage with a 0.01x debt-to-equity ratio, signaling a more conservative balance sheet compared to PACS's 3.36x. On the Piotroski fundamental quality scale (0–9), HCA scores 7/9 vs CCRN's 6/9, reflecting strong financial health.
| Metric | ||||
|---|---|---|---|---|
| ROE (TTM)Return on equity | +20.1% | -27.1% | — | +19.6% |
| ROA (TTM)Return on assets | +3.4% | -19.8% | +11.3% | +5.7% |
| ROICReturn on invested capital | +5.6% | -0.9% | +19.9% | +13.2% |
| ROCEReturn on capital employed | +7.0% | -0.8% | +27.0% | +13.8% |
| Piotroski ScoreFundamental quality 0–9 | 6 | 6 | 7 | 7 |
| Debt / EquityFinancial leverage | 3.36x | 0.01x | — | 1.47x |
| Net DebtTotal debt minus cash | $3.0B | -$106M | $49.2B | $10.3B |
| Cash & Equiv.Liquid assets | $197M | $109M | $1.0B | $2.9B |
| Total DebtShort + long-term debt | $3.2B | $2M | $50.2B | $13.2B |
| Interest CoverageEBIT ÷ Interest expense | — | -1.39x | 5.37x | 4.28x |
Total Returns (Dividends Reinvested)
THC leads this category, winning 4 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in THC five years ago would be worth $29,044 today (with dividends reinvested), compared to $7,746 for CCRN. Over the past 12 months, PACS leads with a +219.6% total return vs CCRN's -5.4%. The 3-year compound annual growth rate (CAGR) favors THC at 40.7% vs CCRN's -17.7% — a key indicator of consistent wealth creation.
| Metric | ||||
|---|---|---|---|---|
| YTD ReturnYear-to-date | -14.9% | +62.4% | -8.6% | -2.7% |
| 1-Year ReturnPast 12 months | +219.6% | -5.4% | +19.7% | +27.4% |
| 3-Year ReturnCumulative with dividends | +46.2% | -44.3% | +57.4% | +178.5% |
| 5-Year ReturnCumulative with dividends | +46.2% | -22.5% | +109.7% | +190.4% |
| 10-Year ReturnCumulative with dividends | +46.2% | -10.5% | +450.5% | +523.4% |
| CAGR (3Y)Annualised 3-year return | +13.5% | -17.7% | +16.3% | +40.7% |
Risk & Volatility
Evenly matched — CCRN and HCA each lead in 1 of 2 comparable metrics.
Risk & Volatility
HCA is the less volatile stock with a 0.29 beta — it tends to amplify market swings less than CCRN's 0.78 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. CCRN currently trades 87.3% from its 52-week high vs HCA's 77.1% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | ||||
|---|---|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 0.64x | 0.78x | 0.29x | 0.71x |
| 52-Week HighHighest price in past year | $43.08 | $14.99 | $556.52 | $247.21 |
| 52-Week LowLowest price in past year | $7.50 | $7.43 | $330.00 | $146.60 |
| % of 52W HighCurrent price vs 52-week peak | +78.0% | +87.3% | +77.1% | +78.5% |
| RSI (14)Momentum oscillator 0–100 | 48.9 | 53.1 | 30.8 | 52.9 |
| Avg Volume (50D)Average daily shares traded | 772K | 552K | 1000K | 1.2M |
Analyst Outlook
HCA leads this category, winning 1 of 1 comparable metric.
Analyst Outlook
Analyst consensus: PACS as "Buy", CCRN as "Hold", HCA as "Buy", THC as "Buy". Consensus price targets imply 38.1% upside for THC (target: $268) vs -18.9% for CCRN (target: $11). HCA is the only dividend payer here at 0.69% yield — a key consideration for income-focused portfolios.
| Metric | ||||
|---|---|---|---|---|
| Analyst RatingConsensus buy/hold/sell | Buy | Hold | Buy | Buy |
| Price TargetConsensus 12-month target | $44.67 | $10.61 | $527.45 | $268.00 |
| # AnalystsCovering analysts | 8 | 14 | 46 | 32 |
| Dividend YieldAnnual dividend ÷ price | — | — | +0.7% | — |
| Dividend StreakConsecutive years of raises | 0 | 1 | 5 | 0 |
| Dividend / ShareAnnual DPS | — | — | $2.94 | — |
| Buyback YieldShare repurchases ÷ mkt cap | 0.0% | +1.6% | +10.5% | +8.4% |
THC leads in 3 of 6 categories (Income & Cash Flow, Valuation Metrics). HCA leads in 2 (Profitability & Efficiency, Analyst Outlook). 1 tied.
PACS vs CCRN vs HCA vs THC: Key Questions Answered
10 questions · data-driven answers · updated daily
01Is PACS or CCRN or HCA or THC a better buy right now?
For growth investors, PACS Group, Inc.
(PACS) is the stronger pick with 29. 3% revenue growth year-over-year, versus -21. 6% for Cross Country Healthcare, Inc. (CCRN). Tenet Healthcare Corporation (THC) offers the better valuation at 12. 5x trailing P/E (10. 9x forward), making it the more compelling value choice. Analysts rate PACS Group, Inc. (PACS) a "Buy" — based on 8 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which has the better valuation — PACS or CCRN or HCA or THC?
On trailing P/E, Tenet Healthcare Corporation (THC) is the cheapest at 12.
5x versus PACS Group, Inc. at 27. 6x. On forward P/E, Tenet Healthcare Corporation is actually cheaper at 10. 9x. The PEG ratio (P/E divided by earnings growth rate) is the most growth-adjusted single valuation metric: Tenet Healthcare Corporation wins at 0. 33x versus HCA Healthcare, Inc. 's 0. 67x — a PEG below 1. 0 traditionally signals the market is underpricing earnings growth.
03Which is the better long-term investment — PACS or CCRN or HCA or THC?
Over the past 5 years, Tenet Healthcare Corporation (THC) delivered a total return of +190.
4%, compared to -22. 5% for Cross Country Healthcare, Inc. (CCRN). Over 10 years, the gap is even starker: THC returned +523. 4% versus CCRN's -10. 5%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
04Which is safer — PACS or CCRN or HCA or THC?
By beta (market sensitivity over 5 years), HCA Healthcare, Inc.
(HCA) is the lower-risk stock at 0. 29β versus Cross Country Healthcare, Inc. 's 0. 78β — meaning CCRN is approximately 172% more volatile than HCA relative to the S&P 500. On balance sheet safety, Cross Country Healthcare, Inc. (CCRN) carries a lower debt/equity ratio of 1% versus 3% for PACS Group, Inc. — giving it more financial flexibility in a downturn.
05Which is growing faster — PACS or CCRN or HCA or THC?
By revenue growth (latest reported year), PACS Group, Inc.
(PACS) is pulling ahead at 29. 3% versus -21. 6% for Cross Country Healthcare, Inc. (CCRN). On earnings-per-share growth, the picture is similar: PACS Group, Inc. grew EPS 221. 1% year-over-year, compared to -565. 9% for Cross Country Healthcare, Inc.. Over a 3-year CAGR, HCA leads at 7. 9% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.
06Which has better profit margins — PACS or CCRN or HCA or THC?
HCA Healthcare, Inc.
(HCA) is the more profitable company, earning 9. 0% net margin versus -9. 0% for Cross Country Healthcare, Inc. — meaning it keeps 9. 0% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: THC leads at 16. 1% versus -0. 3% for CCRN. At the gross margin level — before operating expenses — THC leads at 82. 3%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
07Is PACS or CCRN or HCA or THC more undervalued right now?
The PEG ratio (forward P/E divided by expected earnings growth rate) is the most precise measure of undervaluation relative to growth potential.
By this metric, Tenet Healthcare Corporation (THC) is the more undervalued stock at a PEG of 0. 33x versus HCA Healthcare, Inc. 's 0. 67x. A PEG below 1. 0 is traditionally considered the threshold for growth-adjusted undervaluation. On forward earnings alone, Tenet Healthcare Corporation (THC) trades at 10. 9x forward P/E versus 133. 8x for Cross Country Healthcare, Inc. — 122. 9x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for THC: 38. 1% to $268. 00.
08Which pays a better dividend — PACS or CCRN or HCA or THC?
In this comparison, HCA (0.
7% yield) pays a dividend. PACS, CCRN, THC do not pay a meaningful dividend and should not be held primarily for income.
09Is PACS or CCRN or HCA or THC better for a retirement portfolio?
For long-horizon retirement investors, HCA Healthcare, Inc.
(HCA) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 29), 0. 7% yield, +450. 5% 10Y return). Both have compounded well over 10 years (HCA: +450. 5%, CCRN: -10. 5%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
10What are the main differences between PACS and CCRN and HCA and THC?
These companies operate in different sectors (PACS (Financial Services) and CCRN (Healthcare) and HCA (Healthcare) and THC (Healthcare)), which means they face different economic cycles, regulatory environments, and macro sensitivities — making direct comparison nuanced.
In terms of investment character: PACS is a small-cap high-growth stock; CCRN is a small-cap quality compounder stock; HCA is a mid-cap deep-value stock; THC is a mid-cap deep-value stock. HCA pays a dividend while PACS, CCRN, THC do not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform all of them.
You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.